Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593097 · ClinicalTrials.gov registry record · Phase 3
Metformin for the Prevention of Episodic Migraine (MPEM)
A Phase 3 study of Migraine, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02593097: Completed Phase 3 study of Migraine, sponsored by Mayo Clinic.
NCT02593097 is a Phase 3 study of Migraine that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593097, a Phase 3 study of Migraine, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
Primary Outcome
Total number of moderate and severe headache days
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Matching Placebo
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-06 |
| Phase | Phase 3 |
What the finished NCT02593097 record still lists
NCT02593097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT02593097 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02593097 about?
NCT02593097 is a clinical study titled "Metformin for the Prevention of Episodic Migraine (MPEM)". The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
What is the current status of trial NCT02593097?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2016-02. Estimated completion is 2019-06.
What conditions does trial NCT02593097 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02593097?
The interventions under investigation include: Metformin (DRUG), Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT02593097?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593097 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02593097's enrollment target sits among peer trials
34 89th of 102 higher than 14 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia